Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national
Country
Sector
Themes
Also in
Price· split & dividend adjusted
No price history for this asset yet.
News & notes movingLH
Biotech & Genomic Medicine▲
Labcorp Raises Guidance, Completes Buyback, and Expands Oncology Testing
Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and made Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to guide prostate cancer treatment decisions. The company also recently received FDA approval for its PGDx elio tissue complete CDx for advanced melanoma. These moves reinforce Labcorp's role as a major companion diagnostics provider and signal management confidence through upgraded guidance and sustained buybacks. The PTEN assay rollout and upgraded 2026 guidance support a near-term catalyst around mix shift into precision oncology, though risks such as potential PAMA-related reimbursement cuts and pricing pressure in core lab services remain.
Labcorp Launches First FDA-Approved PTEN Companion Diagnostic for Prostate Cancer
Labcorp announced the nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic to detect PTEN protein loss in prostate adenocarcinoma tumors. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP in combination with abiraterone acetate and prednisone. PTEN loss is associated with more aggressive disease and reduced benefit from standard therapies, and until now no approved treatments specifically targeted this biology. Labcorp participated in Roche's early access program to ensure Day 1 laboratory readiness, and the test is now available through Labcorp's national network, complementing its comprehensive oncology testing portfolio.
Labcorp raises annual profit forecast on strong testing demand
Labcorp raised its annual profit forecast and reported better-than-expected second-quarter results, driven by steady demand for diagnostic testing and growth in its drug-development services business. The company lifted its 2026 adjusted earnings forecast to a range of $18.10 to $18.55 per share, up from $17.70 to $18.35 previously, with the midpoint of $18.33 exceeding analysts' estimate of $18.01. Annual revenue guidance was also raised to between $14.71 billion and $14.83 billion, compared with the prior range of $14.65 billion to $14.80 billion. Overall second-quarter revenue rose 5.8% to $3.73 billion, above estimates of $3.71 billion, and adjusted earnings per share of $4.99 topped expectations of $4.78. Revenue at the Diagnostics Laboratories segment grew 5.5% to $2.90 billion, slightly below the $2.91 billion estimate, while Biopharma Laboratory Services revenue rose 6.5% to $836.2 million, exceeding estimates of $797.3 million.
Labcorp Holdings Draws Fresh Earnings Optimism, Seen 4.3% Undervalued
Labcorp Holdings is attracting fresh earnings optimism ahead of its June 2026 quarter, with analysts raising revenue and year-over-year earnings growth expectations. The stock has gained 11.9% over the past month and 17.9% year to date, closing recently at $296.77. A widely followed narrative pegs fair value at $310.12, implying the shares are 4.3% undervalued, while a discounted cash flow model suggests a much higher intrinsic value of $531.53. However, the current price-to-earnings ratio of 25.8 times sits slightly above the US healthcare industry average of 25.5 times and a modeled fair ratio of 25 times, raising questions about whether sentiment will align with cash flow estimates or if the multiple will contract. Key drivers include AI-powered operational efficiencies from platforms like eClaim Assist and Labcorp Diagnostic Assistant, as well as the Invitae integration, which is expected to be slightly accretive to full-year earnings.
Labcorp Set to Report Q2 Earnings With Revenue Expected to Rise 5.4%
Labcorp is scheduled to report its second-quarter 2026 results on July 30 before the market opens. The Zacks Consensus Estimate for revenues is $3.72 billion, indicating a 5.4% increase from the year-ago period, while the consensus earnings per share estimate of $4.79 suggests a 10.1% improvement. The company has an Earnings ESP of +0.71% and a Zacks Rank of 2, which according to Zacks Investment Research signals a higher likelihood of an earnings beat. Key drivers for the quarter include strong organic growth in Diagnostics Laboratories, supported by health system partnerships and acquisitions, as well as an expanding specialty testing portfolio in areas such as oncology and neurology.
Labcorp Holdings declared a quarterly dividend of $0.72 per share, in line with the previous payout. The dividend is payable on September 11 to shareholders of record as of August 28, with the ex-dividend date also on August 28. The forward yield is 1.04%. The company has now announced a dividend of $0.72 for thirteen consecutive quarters.
Medicare couvrira et remboursera le test NASHnext® de GENFIT aux États-Unis
GENFIT annonce que Medicare couvrira et remboursera NASHnext®, un test sanguin non invasif développé par Labcorp à partir de sa technologie NIS4®, à compter du 10 août 2026. Le remboursement s'élèvera à environ 252 dollars par test dans le cadre du barème des frais de laboratoire clinique. Cette décision vise à faciliter l'adoption à grande échelle du test, qui identifie les patients atteints de MASH à risque, notamment ceux présentant un prédiabète, un diabète de type 2, une obésité ou une dyslipidémie. GENFIT prévoit que cette couverture ouvre la voie à une future prise en charge par les assureurs privés et génère une deuxième source de revenus récurrents, avec plus de détails attendus à l'automne.
Labcorp Launches FDA-Approved ColoSense At-Home Colorectal Cancer Test with Medicare Coverage
Labcorp announced the nationwide availability of ColoSense, the first FDA-approved RNA-based at-home colorectal cancer screening test, now covered for eligible Medicare and Medicare Advantage patients. The test detects RNA biomarkers for both cancer and advanced adenomas and features a simplified at-home collection process. ColoSense is aligned with major U.S. screening guidelines and adds a differentiated option to Labcorp's colorectal screening portfolio. The launch supports the company's diagnostics narrative and has contributed to recent share price strength, though the test is unlikely to significantly impact near-term financials on its own.
Quest Diagnostics wins nationwide Haystack MRD access and expands into psychiatry
Quest Diagnostics received New York State approval for its Haystack MRD liquid biopsy test, enabling nationwide use for detecting residual or recurrent cancer. The approval follows published research indicating the test's high sensitivity for minimal residual disease monitoring. Quest Diagnostics also entered a national partnership with Attunio Health to support an AI-powered precision psychiatry platform, providing scalable laboratory infrastructure for mental health diagnostics across the United States. The Haystack MRD test now has regulatory clearance across all 50 states and clinical backing from major centers such as Memorial Sloan Kettering and City of Hope, positioning Quest to compete more directly with other cancer monitoring players like Guardant Health and Exact Sciences. On the mental health side, serving as the lab backbone for an AI-powered precision psychiatry platform gives Quest a role in turning biological markers into routine psychiatric decision support, an area where competitors such as Labcorp and Mayo Clinic Laboratories are also active.
StockStory flags Veralto, Toll Brothers, and Labcorp as mid-cap stocks to avoid
StockStory highlights three mid-cap stocks it recommends investors avoid: Veralto, Toll Brothers, and Labcorp. Veralto, a water analytics firm spun off from Danaher, posted annual revenue growth of just 4.4% over four years and faces shaky demand with projected sales growth of 6.5%. Toll Brothers, the luxury homebuilder, saw its backlog decline by an average of 9.1% over two years and expects a 2.9% sales drop, while earnings per share contracted 5.7% annually. Labcorp, the laboratory services giant, experienced a 1.6% annual sales decline over five years and an 11.1% annual drop in earnings per share, with organic revenue underperforming.
Labcorp posts weakest Q1 among testing and diagnostics peers
Labcorp reported first-quarter revenues of $3.54 billion, up 5.8% year on year, but delivered the weakest performance against analyst estimates, the slowest revenue growth, and the weakest full-year guidance update among five tracked testing and diagnostics services stocks. The group as a whole beat consensus revenue estimates by 3.2%, with Guardant Health leading on a 48.3% revenue surge to $301.7 million and the biggest guidance raise. RadNet grew revenues 22.1% to $575.6 million but missed EPS estimates significantly, while NeoGenomics and Quest Diagnostics also exceeded revenue expectations. Share prices across the group have risen 20.3% on average since reporting.
Labcorp's Specialty Testing and AI Focus Drive Growth Prospects
Labcorp Holdings is poised for growth driven by expansion in specialty testing areas like oncology and neurology, strategic acquisitions, and AI-powered operational efficiency. In the first quarter of 2026, neurology testing delivered double-digit growth, while oncology benefited from new liquid biopsy tests and wider availability of minimal residual disease solutions. The company's launchpad initiatives target $100 to $125 million in annual savings, and it is collaborating with PathAI, Amazon Web Services, and Datavant on AI platforms. However, macroeconomic pressures and currency headwinds pose risks, with cost of revenues rising 5.3% year over year in the first quarter. The Zacks Consensus Estimate for 2026 earnings per share is $18.00, and revenues are pegged at $14.71 billion, implying 5.4% growth.
Labcorp Holdings Stock Underperforms the Nasdaq Despite Strong Q1 Results
Labcorp Holdings Inc. has underperformed the Nasdaq Composite over multiple time frames, even after reporting first-quarter results that beat expectations. The company's shares have declined 4.1% over the past three months, while the Nasdaq gained 15.8% in the same period. On a year-to-date basis, Labcorp rose 3.5% versus the Nasdaq's 12% gain, and over the past 52 weeks it climbed marginally compared to the Nasdaq's 33.3% return. The stock has been trading below its 50-day and 200-day moving averages since early March. In its first quarter, Labcorp posted adjusted earnings per share of $4.25 on revenue of $3.54 billion, surpassing analyst forecasts of $4.09 and $3.50 billion respectively, and it guided full-year adjusted EPS in the range of $17.70 to $18.35. Wall Street analysts remain bullish with a consensus Strong Buy rating and a mean price target of $311.12, implying a potential upside of 19.9% from current levels.